Discovery of candidate phospholipid biomarkers in human lipoproteins with coronary artery disease by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry

Seul Kee Byeon, Ju Yong Lee, Sangsoo Lim, Donghoon Choi, Myeong Hee Moon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In this study, an analytical method is demonstrated to identify and develop potential phospholipid (PL) biomarkers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in plasma from individuals with coronary artery disease (CAD) by employing a combination of off-line multiplexed hollow fiber flow field-flow fractionation (MxHF5) and nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry (nLC-ESI-MS-MS). HDL and LDL particles of human plasma were sorted by size at a semi-preparative scale using MxHF5, after which PL extracts of each lipoprotein fraction were qualitatively and quantitatively analyzed by nLC-ESI-MS-MS. Experiments were performed using plasma samples from 10 CAD patients and 10 controls. Quantitative analysis of the 93 PL species identified yielded a selection of 19 species from HDL fractions and 10 from LDL fractions exhibiting at least a five fold change in average concentration in CAD patients. Among the selected species, only a few were found exclusively in patient HDL fractions (18:3-LPA and 20:2/16:0-PG), control HDL fractions (16:0/16:1-PC, 20:1/20:4-PE, and 16:1-LPA), and control LDL fractions (16:0/22:3-PG). Moreover, 16:1/18:2-PC was detected from both HDL and LDL fractions of controls but disappeared in CAD patients. Although the typical change in lipoproteins for CAD is well known, with decreased levels of HDLs and reduced LDL particle size, the current study provides fundamental information on the molecular level of lipoprotein variation which can be utilized for diagnostic and therapeutic tracking.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalJournal of Chromatography A
Volume1270
DOIs
Publication statusPublished - 2012 Dec 28

Fingerprint

Field Flow Fractionation
Liquid chromatography
Biomarkers
HDL Lipoproteins
Fractionation
Tandem Mass Spectrometry
LDL Lipoproteins
Liquid Chromatography
Lipoproteins
Mass spectrometry
Coronary Artery Disease
Phospholipids
Flow fields
Plasma (human)
Plasmas
Electrospray ionization
Electrospray Ionization Mass Spectrometry
Particle Size
Particle size
Fibers

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry
  • Organic Chemistry

Cite this

@article{99a9e945049e4d07a5276197c3b952a1,
title = "Discovery of candidate phospholipid biomarkers in human lipoproteins with coronary artery disease by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry",
abstract = "In this study, an analytical method is demonstrated to identify and develop potential phospholipid (PL) biomarkers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in plasma from individuals with coronary artery disease (CAD) by employing a combination of off-line multiplexed hollow fiber flow field-flow fractionation (MxHF5) and nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry (nLC-ESI-MS-MS). HDL and LDL particles of human plasma were sorted by size at a semi-preparative scale using MxHF5, after which PL extracts of each lipoprotein fraction were qualitatively and quantitatively analyzed by nLC-ESI-MS-MS. Experiments were performed using plasma samples from 10 CAD patients and 10 controls. Quantitative analysis of the 93 PL species identified yielded a selection of 19 species from HDL fractions and 10 from LDL fractions exhibiting at least a five fold change in average concentration in CAD patients. Among the selected species, only a few were found exclusively in patient HDL fractions (18:3-LPA and 20:2/16:0-PG), control HDL fractions (16:0/16:1-PC, 20:1/20:4-PE, and 16:1-LPA), and control LDL fractions (16:0/22:3-PG). Moreover, 16:1/18:2-PC was detected from both HDL and LDL fractions of controls but disappeared in CAD patients. Although the typical change in lipoproteins for CAD is well known, with decreased levels of HDLs and reduced LDL particle size, the current study provides fundamental information on the molecular level of lipoprotein variation which can be utilized for diagnostic and therapeutic tracking.",
author = "Byeon, {Seul Kee} and Lee, {Ju Yong} and Sangsoo Lim and Donghoon Choi and Moon, {Myeong Hee}",
year = "2012",
month = "12",
day = "28",
doi = "10.1016/j.chroma.2012.11.012",
language = "English",
volume = "1270",
pages = "246--253",
journal = "Journal of Chromatography",
issn = "0021-9673",
publisher = "Elsevier",

}

TY - JOUR

T1 - Discovery of candidate phospholipid biomarkers in human lipoproteins with coronary artery disease by flow field-flow fractionation and nanoflow liquid chromatography-tandem mass spectrometry

AU - Byeon, Seul Kee

AU - Lee, Ju Yong

AU - Lim, Sangsoo

AU - Choi, Donghoon

AU - Moon, Myeong Hee

PY - 2012/12/28

Y1 - 2012/12/28

N2 - In this study, an analytical method is demonstrated to identify and develop potential phospholipid (PL) biomarkers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in plasma from individuals with coronary artery disease (CAD) by employing a combination of off-line multiplexed hollow fiber flow field-flow fractionation (MxHF5) and nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry (nLC-ESI-MS-MS). HDL and LDL particles of human plasma were sorted by size at a semi-preparative scale using MxHF5, after which PL extracts of each lipoprotein fraction were qualitatively and quantitatively analyzed by nLC-ESI-MS-MS. Experiments were performed using plasma samples from 10 CAD patients and 10 controls. Quantitative analysis of the 93 PL species identified yielded a selection of 19 species from HDL fractions and 10 from LDL fractions exhibiting at least a five fold change in average concentration in CAD patients. Among the selected species, only a few were found exclusively in patient HDL fractions (18:3-LPA and 20:2/16:0-PG), control HDL fractions (16:0/16:1-PC, 20:1/20:4-PE, and 16:1-LPA), and control LDL fractions (16:0/22:3-PG). Moreover, 16:1/18:2-PC was detected from both HDL and LDL fractions of controls but disappeared in CAD patients. Although the typical change in lipoproteins for CAD is well known, with decreased levels of HDLs and reduced LDL particle size, the current study provides fundamental information on the molecular level of lipoprotein variation which can be utilized for diagnostic and therapeutic tracking.

AB - In this study, an analytical method is demonstrated to identify and develop potential phospholipid (PL) biomarkers of high density lipoprotein (HDL) and low density lipoprotein (LDL) in plasma from individuals with coronary artery disease (CAD) by employing a combination of off-line multiplexed hollow fiber flow field-flow fractionation (MxHF5) and nanoflow liquid chromatography-electrospray ionization-tandem mass spectrometry (nLC-ESI-MS-MS). HDL and LDL particles of human plasma were sorted by size at a semi-preparative scale using MxHF5, after which PL extracts of each lipoprotein fraction were qualitatively and quantitatively analyzed by nLC-ESI-MS-MS. Experiments were performed using plasma samples from 10 CAD patients and 10 controls. Quantitative analysis of the 93 PL species identified yielded a selection of 19 species from HDL fractions and 10 from LDL fractions exhibiting at least a five fold change in average concentration in CAD patients. Among the selected species, only a few were found exclusively in patient HDL fractions (18:3-LPA and 20:2/16:0-PG), control HDL fractions (16:0/16:1-PC, 20:1/20:4-PE, and 16:1-LPA), and control LDL fractions (16:0/22:3-PG). Moreover, 16:1/18:2-PC was detected from both HDL and LDL fractions of controls but disappeared in CAD patients. Although the typical change in lipoproteins for CAD is well known, with decreased levels of HDLs and reduced LDL particle size, the current study provides fundamental information on the molecular level of lipoprotein variation which can be utilized for diagnostic and therapeutic tracking.

UR - http://www.scopus.com/inward/record.url?scp=84872265484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872265484&partnerID=8YFLogxK

U2 - 10.1016/j.chroma.2012.11.012

DO - 10.1016/j.chroma.2012.11.012

M3 - Article

C2 - 23195705

AN - SCOPUS:84872265484

VL - 1270

SP - 246

EP - 253

JO - Journal of Chromatography

JF - Journal of Chromatography

SN - 0021-9673

ER -